Spots Global Cancer Trial Database for hormone receptor positive breast cancer
Every month we try and update this database with for hormone receptor positive breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | NCT03401385 | Hormone Recepto... Triple Negative... Non-small Cell ... | Datopotamab Der... Steroid Contain... Non-Steroid Con... | 18 Years - | Daiichi Sankyo | |
| Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | NCT04443348 | Triple Negative... Hormone Recepto... Biopsy-proven, ... | Radiation Thera... Pembrolizumab Paclitaxel Carboplatin Cyclophosphamid... Doxorubicin Capecitabine | 18 Years - | Massachusetts General Hospital | |
| Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | NCT01698918 | Hormone Recepto... | Everolimus Letrozole Exemestane Alcohol-free de... Standard of car... | 18 Years - | Novartis | |
| Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms | NCT02118636 | Breast Cancer Arthralgia | 21 Years - | University of Michigan Rogel Cancer Center | ||
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | NCT06120283 | Advanced Solid ... Advanced Breast... Metastatic Brea... Hormone-recepto... Hormone Recepto... Hormone Recepto... HER2-negative B... Hormone Recepto... Non-small Cell ... | BGB-43395 Fulvestrant Letrozole | 18 Years - | BeiGene | |
| Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer | NCT00717015 | Breast Cancer | 18 Years - | National University Hospital, Singapore | ||
| A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer | NCT04699630 | Metastatic Brea... Locally Advance... | U3-1402 | 18 Years - | SCRI Development Innovations, LLC | |
| Efficacy and Safety of 500mg of Fulvestrant | NCT00585507 | Breast Cancer | Fulvestrant | 18 Years - | Beth Israel Deaconess Medical Center | |
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | NCT05565417 | Non Small Cell ... Head and Neck S... Triple Negative... Cutaneous Squam... Hormone Recepto... Small Bowel Can... Esophageal Canc... Colorectal Canc... Diffuse Large B... Hodgkin Lymphom... Burkitt Lymphom... Follicular Lymp... | IMT-009 Fruquintinib | 18 Years - | Immunitas Therapeutics | |
| Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | NCT02820961 | Breast Cancer Estrogen Recept... | entinostat exemestane | 18 Years - 85 Years | Syndax Pharmaceuticals | |
| Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms | NCT02118636 | Breast Cancer Arthralgia | 21 Years - | University of Michigan Rogel Cancer Center | ||
| Secondary Adjuvant Long Term Study With Arimidex | NCT00295620 | Breast Cancer | Anastrozole | 18 Years - 80 Years | AstraZeneca | |
| 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer | NCT00300508 | Breast Neoplasm... | Anastrozole | - 80 Years | AstraZeneca | |
| Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy | NCT00050011 | Breast Neoplasm... Osteoporosis | Zoledronic Acid Letrozole | 18 Years - 85 Years | Novartis | |
| Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer | NCT00717015 | Breast Cancer | 18 Years - | National University Hospital, Singapore | ||
| A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer | NCT02675231 | Hormone Recepto... HER-2 Positive ... | Abemaciclib Trastuzumab Fulvestrant Standard of Car... | 18 Years - | Eli Lilly and Company | |
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | NCT04569747 | HER2-positive B... Invasive Carcin... Breast Cancer Node Negative B... Micrometastasis... Hormone Recepto... | Pertuzumab+TRAS... ADJUVANT ENDOCR... | 18 Years - | Dana-Farber Cancer Institute | |
| A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. | NCT01602380 | Hormone Recepto... | faslodex 500mg arimidex 1mg faslodex dummy arimidex dummy | 18 Years - 130 Years | AstraZeneca | |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | NCT06120283 | Advanced Solid ... Advanced Breast... Metastatic Brea... Hormone-recepto... Hormone Recepto... Hormone Recepto... HER2-negative B... Hormone Recepto... Non-small Cell ... | BGB-43395 Fulvestrant Letrozole | 18 Years - | BeiGene | |
| Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women | NCT01069211 | Breast Cancer | - | Korean Breast Cancer Study Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
